What are the appropriate cough suppressants, dosing, and contraindications for an adult with a non‑productive cough?

Cough Suppressants for Non-Productive Cough in Adults

For adults with non-productive (dry) cough, the choice of suppressant depends critically on the underlying cause: use codeine or dextromethorphan for chronic bronchitis, ipratropium bromide for URI or bronchitis, but avoid central suppressants for URI-related cough as they lack efficacy.

Algorithm for Selecting Cough Suppressants

Step 1: Identify the Underlying Cause

The effectiveness of cough suppressants varies dramatically based on etiology, making diagnosis essential before treatment 1:

For Chronic Bronchitis:

• Central suppressants (codeine, dextromethorphan) are recommended for short-term symptomatic relief 1
  • Codeine: 7.5-60 mg orally, with doses of 30 mg showing 40-47% reduction in cough frequency 1
  • Dextromethorphan: 30 mg orally as alternative
  • Grade of recommendation: B (fair evidence, intermediate benefit) 1
  • These agents work centrally through brainstem receptors 2

For Upper Respiratory Infection (URI) or Acute Bronchitis:

• Ipratropium bromide (inhaled anticholinergic) is the only recommended inhaled agent 1
  • Grade of recommendation: A (fair evidence, substantial benefit) 1
  • This is a critical distinction: other anticholinergics are not supported by evidence

For URI-Related Cough:

• Central suppressants (codeine, dextromethorphan) are NOT recommended despite common use 1
  • Grade of recommendation: D (good evidence, no benefit) 1
  • Studies show no difference in cough frequency, severity, or objective measures 1

Step 2: Consider Alternative Agents

Peripheral Cough Suppressants:

• Levodropropizine and moguisteine are recommended for chronic or acute bronchitis (Grade A) but have limited efficacy for URI (Grade D) 1, 3
• These show the highest level of benefit, particularly in certain populations 3
• Not widely available in the United States 1

Butamirate citrate:

• Acts centrally through brainstem receptors with additional bronchodilator and anti-inflammatory effects 4
• Rapid absorption with therapeutic levels in 5-10 minutes 4
• Side effects rare (0.5-1%): rash, nausea, diarrhea, dizziness 4

Step 3: Avoid Common Pitfalls

What NOT to Use:

• Over-the-counter combination cold medications (except older antihistamine-decongestant combinations): Grade D recommendation 1
• Albuterol for non-asthmatic cough: Grade D recommendation 1
• Zinc preparations for common cold: Grade D recommendation 1
• Mucolytic agents (agents altering mucus characteristics) for chronic bronchitis: Grade D recommendation 1

Dosing Specifics

Codeine (for chronic bronchitis only):

• Starting dose: 7.5-30 mg orally
• Effective dose typically 30 mg, showing 40-60% reduction in cough counts 1
• Use for short-term symptomatic relief only 1

Dextromethorphan (for chronic bronchitis only):

• Typical dose: 30 mg orally 1
• Alternative to codeine with similar central mechanism 2

Ipratropium bromide (for URI or bronchitis):

• Inhaled formulation
• Specific dosing not detailed in guidelines but follows standard nebulizer protocols

Contraindications and Cautions

Codeine and opioid derivatives:

• Sedation is common but may be beneficial if cough disturbs sleep 2
• Standard opioid precautions apply (respiratory depression, addiction potential, drug interactions)
• Low-dose oral morphine shows efficacy but side effect profile limits widespread use 5

First-generation antihistamines (e.g., chlorpheniramine):

• Often combined with codeine 2
• Sedation may be valuable for sleep disturbance 2
• Avoid in patients requiring alertness

General contraindications:

• Productive cough with significant sputum should not be suppressed
• Neuromuscular impairment: protussive agents are ineffective and contraindicated (Grade D) 1

Critical Evidence Considerations

The ACCP guidelines 1 represent the highest quality evidence available, though from 2006. Key points:

• Strong evidence exists against using central suppressants for URI, despite their widespread use and availability 1
• The dissociation between patient-reported relief and objective cough measures suggests subjective benefit may occur even without measurable efficacy 6, 5
• Treatment should be guided by specific knowledge of the disorder causing cough, not empiric suppression 1

The most important clinical decision is distinguishing chronic bronchitis from URI-related cough, as this completely changes the recommended approach.